Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms

Frontiers in Neuroscience

Volumn , Issue SEP, 2011, Pages

  Roberds, Steven L ^a   Filippov, Igor ^b   Alexandrov, Vadim ^b   Hanania, Taleen ^b   Brunner, Dani ^b  

^a PFIZER INC   (United States)

^b PSYCHOGENICS INC   (United States)

Author keywords

Antipsychotic; Anxiolytic; Behavioral models; Computer vision; Drug development; High throughput screening; Machine learning; Mouse

Indexed keywords

ANXIOLYTIC AGENT; NEUROLEPTIC AGENT; PF 670462; TP 10; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COMPUTER SYSTEM; COMPUTER VISION ENABLED SYSTEM; CONTROLLED STUDY; DEPRESSION; DRUG SCREENING; MENTAL DISEASE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; SCHIZOPHRENIA;

EID: 84862180408     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2011.00103     Document Type: Article

References (12)

1. Badura, L., Swanson, T., Adamowicz, W., Adams, J., Cianfrogna, J., Fisher, K., Holland, J., Kleiman, R., Nelson, F., Reynolds, L., St Germain, K., Scha-effer, E., Tate, B., and Sprouse, J. (2007). An inhibitor of casein kinase iïμ induces phase delays in circa-dian rhythms under free-running and entrained conditions. J. Pharmacol. Exp. Ther. 322, 730-738.
2. Benca, R., Duncan, M. J., Frank, E., McClung, C., Nelson, R. J., and Vicentic, A. (2009). Biological rhythms, higher brain function, and behavior: gaps, opportunities, and challenges. Brain Res. Rev. 62, 57-70.
3. Brunner, D., Nestler, E., and Leahy, E. (2002). In need of high-throughput behavioral systems. Drug Discov. Today 7, S107-S112.
4. Bryant, C. D., Graham, M. E., Distler, M. G., Munoz, M. B., Li, D., Vez-ina, P., Sokoloff, G., and Palmer, A. A. (2009). A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphet-amine. Psychopharmacology (Berl.) 203, 703-711.
5. Crawley, J. N., and Paylor, R. (1997). A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31, 197-211.
6. Gleason, S. D., and Shannon, H. E. (1997). Blockade of phencyclidine-induced hyperlocomotion by olan-zapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl.) 129, 79-84.
7. Ishii, D., Matsuzawa, D., Kanahara, N., Matsuda, S., Sutoh, C., Oht-suka, H., Nakazawa, K., Kohno, M., Hashimoto, K., Iyo, M.,and Shimizu, E (2010). Effects of aripiprazole on MK-801-induced prepulse inhibi tion deficits and mitogen-activated protein kinase signal transduc-tion pathway. Neurosci. Lett. 471, 53-57.
8. Kokel, D., Bryan, J., Laggner, C., White, R., Cheung, C. Y. J., Mateus, R., Healey, D., Kim, S., Werdich, A. A., Haggarty, S. J., Macrae, C. A., Shoichet, B., and Peterson, R. T. (2010). Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat. Chem. Biol. 6, 231-237.
9. Lee, C., Etchegaray, J.-P., Cagampang, F R. A., Loudon, A. S. I., and Reppert, S. M. (2001). Posttrans-lational mechanisms regulate the mammalian circadian clock. Cell 107, 855-867.
10. Powell, S. B., Young, J. W., Ong, J. C., Caron, M. G., and Geyer, M. A. (2008). Atypical antipsy-chotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav. Pharmacol. 19, 562-565.
11. Schmidt, C. J., Chapin, D. S., Cian-frogna, J., Corman, M. L., Hajos, M., Harms, J. F., Hoffman, W. E., Lebel, L. A., McCarthy, S. A., Nelson, F. R., Proulx-LaFrance, C., Majchrzak, M. J., Ramirez, A. D., Schmidt, K., Seymour, P. A., Siuciak, J. A., Tingley, F. D. III., Williams, R. D., Verhoest, P. R., and Menniti, F. S. (2008). Pre-clinical characterization of selective phosphodiesterase 10a inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 325, 681-690.
12. Strick, C. A., Schmidt, C. J., and Menniti, F. S. (2007). "PDE10A: a striatum-enriched, dual-substrate phosphodiesterase," in Cyclic NucleotidePhosphodiesterases Health Disease, eds J. A. Beavo, S. H. Francis, and M. D. Houslay (Boca Raton, FL: CRC Press), 237-254.